Answer
With Tzield (teplizumab), a lactating woman may interrupt breastfeeding and pump and discard milk during treatment and for 20 days after administration to minimise infant exposure; data on its presence in human milk, milk production and effects on breastfed children are unavailable.
Sources for this answer
- Tzield 2 mg/2 mL concentrate for solution for infusionSANOFI · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 1Document updated
Sources checked